Aclaris Therapeutics Inc (OQ:ACRS)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

May 07, 2024 04:01 pm ET

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a...

Apr 30, 2024 07:00 am ET

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024...

Apr 23, 2024 08:00 am ET

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will c

Feb 27, 2024 07:00 am ET

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Jan 22, 2024 08:31 am ET

Thinking about buying stock in KE Holdings, Ford Motor, Vertiv Holdings, Cadrenal Therapeutics, or Aclaris Therapeutics?

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEKE, F, VRT, CVKD, and ACRS.

Jan 16, 2024 07:00 am ET

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review of...

Jan 10, 2024 07:00 am ET

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an...

Dec 19, 2023 04:01 pm ET

Aclaris Therapeutics Provides Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates. First, Aclaris announced the publication of the...

Dec 05, 2023 04:01 pm ET

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc....

Nov 13, 2023 07:00 am ET

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an...

Nov 06, 2023 07:00 am ET

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Oct 03, 2023 07:00 am ET

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b...

Sep 20, 2023 07:00 am ET

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a...

Sep 18, 2023 07:00 am ET

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive results from ATI-2138-PKPD-102, a Phase 1 Multiple...

Aug 07, 2023 07:00 am ET

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jun 13, 2023 07:01 am ET

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial...

Jun 02, 2023 07:00 am ET

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in two...

May 08, 2023 07:00 am ET

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 02, 2023 07:01 am ET

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on...

Mar 27, 2023 07:00 am ET

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a...

Mar 06, 2023 07:00 am ET

Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced preliminary topline results from a 12-week, Phase 2a, multicenter,...

Feb 23, 2023 07:00 am ET

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Feb 09, 2023 04:01 pm ET

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a...

Jan 06, 2023 07:01 am ET

Aclaris Therapeutics Provides 2023 Outlook

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023. “2023 is setting up to be an...

Nov 29, 2022 07:00 am ET

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic...

Nov 22, 2022 04:01 pm ET

Aclaris Therapeutics Announces Key Leadership Transitions

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023,...

Nov 10, 2022 04:01 pm ET

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the company will participate in two November healthcare...

Nov 08, 2022 07:00 am ET

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Sep 27, 2022 07:00 am ET

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President,...

Aug 30, 2022 07:00 am ET

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a...

Aug 25, 2022 07:00 am ET

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lilly and Company...

Aug 03, 2022 07:00 am ET

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Aug 01, 2022 07:00 am ET

Aclaris Therapeutics Expands Leadership Team

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as President and...

Jun 27, 2022 07:00 am ET

Aclaris Therapeutics Expands Leadership Team

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Gail Cawkwell, MD, PhD, as Chief Medical Officer,...

Jun 01, 2022 04:01 pm ET

Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate...

May 16, 2022 07:00 am ET

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually...

May 10, 2022 07:00 am ET

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 03, 2022 07:00 am ET

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith,...

Feb 24, 2022 07:00 am ET

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Feb 02, 2022 07:00 am ET

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate...

Feb 01, 2022 04:01 pm ET

Aclaris Therapeutics Expands Leadership Team

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of James Loerop as Chief Business Officer, effective...

Jan 11, 2022 04:01 pm ET

Aclaris Therapeutics Provides R&D Update

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on...

Dec 27, 2021 07:00 am ET

Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate...

Dec 03, 2021 07:00 am ET

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the publication of preclinical research of zunsemetinib in...

Nov 18, 2021 04:01 pm ET

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021...

Nov 03, 2021 07:00 am ET

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor...

Nov 02, 2021 07:00 am ET

Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Sep 20, 2021 08:00 am ET

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aclaris Therapeutics, Inc. – ACRS

Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Aclaris Therapeutics,...

Aug 27, 2021 04:01 pm ET

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) will be held on...

Aug 26, 2021 04:01 pm ET

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor...

Aug 05, 2021 07:00 am ET

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Jul 08, 2021 07:00 am ET

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate...

Jun 09, 2021 07:55 pm ET

Aclaris Announces Pricing of Public Offering of Common Stock

Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares...

Jun 08, 2021 04:15 pm ET

Aclaris Announces Proposed Public Offering of Common Stock

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, $75...

Jun 08, 2021 07:00 am ET

Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive preliminary topline results from its first in human Phase...

May 17, 2021 07:00 am ET

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a...

May 07, 2021 07:00 am ET

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Mar 15, 2021 07:00 am ET

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has completed enrollment in its Phase 2a clinical trial of...

Feb 25, 2021 07:00 am ET

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Feb 22, 2021 07:00 am ET

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a...

Feb 10, 2021 07:00 am ET

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the...

Jan 20, 2021 08:45 am ET

Aclaris Announces Pricing of Public Offering of Common Stock

Jan 19, 2021 04:01 pm ET

Aclaris Announces Proposed Public Offering of Common Stock

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions,...

Jan 19, 2021 07:00 am ET

Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive preliminary topline results from a 12-week, Phase 2a,...

Dec 17, 2020 08:31 am ET

Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV.

Dec 15, 2020 07:00 am ET

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board consisting of...

Nov 16, 2020 04:01 pm ET

Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the...

Nov 04, 2020 07:00 am ET

Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Oct 20, 2020 07:00 am ET

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatiti

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris’ Phase 2a clinical...

Sep 01, 2020 04:01 pm ET

Aclaris Therapeutics to Present at Upcoming Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming virtual...

Aug 07, 2020 07:00 am ET

Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights

Jul 07, 2020 04:01 pm ET

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND)...

Jun 17, 2020 10:30 am ET

Thinking about buying stock in Biocept, TOP Ships, Aclaris Therapeutics, Seanergy Maritime, or InnerWorkings?

NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, TOPS, ACRS, SHIP, and INWK.

Jun 17, 2020 07:01 am ET

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that the FDA has allowed an investigational new drug application...

Jun 03, 2020 07:00 am ET

Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced the publication of an abstract at the 2020 European Congress of...

May 26, 2020 04:01 pm ET

Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on...

May 07, 2020 04:01 pm ET

Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the first quarter of 2020 and provided research and development (R&D) and...

Mar 31, 2020 04:01 pm ET

Aclaris Therapeutics Secures $11 Million Term Loan Facility

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank (“SVB”) pursuant to which Aclaris has borrowed $11.0 million....

Feb 25, 2020 04:01 pm ET

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year 2019 and provided research and development...

Feb 19, 2020 05:00 pm ET

Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the fourth quarter and full year 2019, Tuesday, February 25th, after...

Feb 10, 2020 07:00 am ET

Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Jan 09, 2020 04:27 pm ET

Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced positive results from ATI-450-PKPD-101, a Single Ascending Dose and Multiple Ascending Dose (SAD/MAD)...

Jan 08, 2020 08:00 am ET

Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appointment of Vincent Milano to its board of directors, effective January 7, 2020. Vincent Milano...

Nov 27, 2019 03:23 pm ET

Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)

Shareholder rights law firm Robbins LLP announces that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a derivative complaint against the company's officers and directors for breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and alleged vio

Nov 21, 2019 11:39 am ET

Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)

Nov 12, 2019 04:01 pm ET

Aclaris Therapeutics to Present at Upcoming Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at the following conferences: Dr. Neal Walker, President and Chief Executive...

Nov 07, 2019 04:01 pm ET

Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the third quarter of 2019 and provided business highlights and an update on its...

Oct 31, 2019 04:01 pm ET

Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the third quarter 2019, Thursday, November 7th, after U.S. financial...

Oct 24, 2019 04:01 pm ET

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced positive results from its second Phase 3 clinical trial, THWART-1 (WART-301), of A-101 45% Topical...

Oct 10, 2019 04:02 pm ET

Aclaris Therapeutics Announces Divestiture of RHOFADE®

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has divested RHOFADE® (oxymetazoline hydrochloride) cream, 1% (RHOFADE) and related intellectual...

Oct 08, 2019 05:01 pm ET

Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the company, together with Allergan, Inc., has filed a patent infringement lawsuit in the United...

Oct 06, 2019 10:00 am ET

Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of PriceSmart, Inc. (NASDAQ: PSMT), Pyxus International, Inc. (NYSE: PYX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Zimmer Biomet Holdings, Inc. (NYSE: ZBH) on behalf of...

Sep 30, 2019 10:44 am ET

FINAL SEPT. 30 DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important Deadline in Securities Class Action – ACRS

Sep 28, 2019 10:00 am ET

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (NYSE: ACRS) securities between May 8, 2018 and June 29, 2019 (the “Class Period”). Investors have until September 30, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Sep 27, 2019 03:00 pm ET

Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Sep 27, 2019 11:00 am ET

DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Sep 26, 2019 04:45 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS

NEW YORK, Sept. 26, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-08284, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired publicly traded Aclaris securities between May 8, 2018, and June 20, 2019, inclusive (the "Class Period"), seeking to pursue remedies under

Sep 26, 2019 04:45 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS

NEW YORK, Sept. 26, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-08284, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired publicly traded Aclaris securities between May 8, 2018, and June 20, 2019, inclusive (the "Class Period"), seeking to pursue remedies

Sep 26, 2019 11:17 am ET

Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS

Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover...

Sep 25, 2019 08:48 pm ET

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact t

NEW YORK, Sept. 25, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (NASDAQ: ACRS) securities between May 8, 2018 and June 29, 2019 (the "Class Period"). Investors have until September 30, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Sep 25, 2019 03:38 pm ET

ACLARIS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - September 25, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) ("Aclaris" or the "Company") of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Sep 25, 2019 11:00 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS)...

Sep 24, 2019 03:15 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – ACRS

Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) and certain of its officers. The class action, filed in United States District Court, for the...

Sep 24, 2019 03:09 pm ET

Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class Period”). The lawsuit seeks to...

Sep 24, 2019 01:05 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - September 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) ("Aclaris" or the "Company") of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Sep 23, 2019 09:35 am ET

7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities...

Sep 20, 2019 03:00 pm ET

GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC

Sep 20, 2019 11:31 am ET

GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS

Sep 20, 2019 11:00 am ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming September 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”)...

Sep 18, 2019 07:51 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aclaris Therapeutics, Carbonite, GTT Communications, and Just Energy and Encourages Investors to Contac

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Aclaris Therapeutics, Inc. (NYSE: ACRS), Carbonite, Inc. (NASDAQ: CARB), GTT Communications, Inc. (NYSE: GTT), and Just Energy...

Sep 17, 2019 08:49 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – ACRS

Sep 17, 2019 09:31 am ET

Thinking about buying stock in Aclaris Therapeutics, Alder Biopharmaceuticals, Capricor Therapeutics, Canopy Growth, or ConocoPhillips?

NEW YORK, Sept. 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACRS, ALDR, CAPR, CGC, and COP.

Sep 17, 2019 07:00 am ET

Aclaris Therapeutics to Hold R&D Day

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug candidates for...

Sep 16, 2019 04:15 pm ET

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45%...

Sep 16, 2019 09:35 am ET

UPCOMING DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th

Sep 16, 2019 09:14 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities...

Sep 13, 2019 03:00 pm ET

SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) and certain of its officers, on behalf of...

Sep 12, 2019 06:20 pm ET

GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class Period”) of the important September 30, 2019 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Aclaris investors under the federal securities laws.

Sep 12, 2019 02:52 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – ACRS

Sep 10, 2019 07:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investor

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and...

Sep 10, 2019 03:00 pm ET

NATIONALLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CO

Sep 10, 2019 11:36 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Sep 09, 2019 12:55 pm ET

Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 8, 2018 and June 20, 2019. Aclaris, a pharmaceuti

Sep 09, 2019 11:25 am ET

UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact

Sep 05, 2019 06:46 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action against Aclaris Therapeutics Inc. and Certain Officers – ACRS

Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) and certain of its officers. The class action, filed in United States District Court, for the Southern...

Sep 05, 2019 08:30 am ET

Aclaris Therapeutics Announces New Strategic Direction

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the completion of a strategic review of its business, as a result of which the Company...

Sep 04, 2019 11:15 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Sep 03, 2019 10:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Carbonite and Encourages Investors to Co

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), and Carbonite,...

Sep 03, 2019 10:25 am ET

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

Sep 02, 2019 02:00 pm ET

HIGHLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS

Aug 29, 2019 11:51 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Aug 29, 2019 01:23 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....

Aug 28, 2019 11:05 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - August 28, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) ("Aclaris" or the "Company") of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Aug 27, 2019 10:35 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the F

Aug 27, 2019 08:00 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oasmia Pharmaceutical, Aclaris Therapeutics, Evolent Health, and International Flavors & Fragrances and

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), Evolent Health, Inc. (NYSE: EVH), and...

Aug 26, 2019 10:11 pm ET

ACRS: Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS

Aug 24, 2019 10:10 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

NEW YORK, Aug. 24, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

Aug 24, 2019 10:10 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

Aug 24, 2019 09:40 am ET

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In OASM, ACRS, GTT or JE To Contact The Firm

New York, New York--(Newsfile Corp. - August 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, encourages investors in the following companies to contact the firm:

Aug 20, 2019 04:01 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Aug 20, 2019 12:32 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Aug 20, 2019 11:15 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

Aug 18, 2019 07:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Con

Aug 16, 2019 02:38 pm ET

Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS

Aug 15, 2019 05:38 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Aug 15, 2019 10:00 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - August 15, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) ("Aclaris" or the "Company") of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Aug 13, 2019 10:15 am ET

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aclaris Therapeutics, Inc. (“Aclaris” or “theCompany”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities...

Aug 12, 2019 04:00 pm ET

ROSEN, A LEADING LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS

Aug 12, 2019 01:00 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Aug 11, 2019 07:25 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 3M Company, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of 3M Company (NYSE: MMM), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Curaleaf Holdings, Inc. (Other OTC: CURLF)....

Aug 10, 2019 12:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Aug 09, 2019 07:00 pm ET

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ACRS

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class...

Aug 08, 2019 04:01 pm ET

Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced its financial results for the second quarter of 2019, and provided a business strategy...

Aug 07, 2019 04:00 pm ET

ACLARIS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Sou

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased or otherwise...

Aug 06, 2019 07:49 pm ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc.

Aug 05, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, 3M Company, and Aclaris Therapeutics and Encourages Investors to C

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc, Oasmia Pharmaceutical AB, 3M Company, and Aclaris Therapeutics, Inc. Stockholders have until the deadlines...

Aug 05, 2019 07:15 pm ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc.

Aug 05, 2019 07:08 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Aug 05, 2019 10:00 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the F

Aug 02, 2019 06:30 pm ET

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ACRS

NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Aclaris investors under the federal securities laws.

Aug 01, 2019 05:53 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Aug 01, 2019 11:18 am ET

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ:

Aug 01, 2019 07:00 am ET

Aclaris Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced it will report financial results for the second quarter 2019, Thursday, August 8th,...

Jul 31, 2019 06:54 pm ET

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ:

Jul 31, 2019 06:15 pm ET

Shareholder Alert: Robbins Arroyo LLP Announces Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between May 8, 2018 and June 20, 2019. Aclaris is a pharmaceutical company that identifies, develops, and commercial

Jul 31, 2019 05:47 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

NEW YORK, July 31, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jul 31, 2019 04:41 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) securities between May 8, 2018 and June 20, 2019, inclusive (the “Class Period”). Aclaris investors have until September 30, 2019 to file a lead pla

Jul 31, 2019 01:13 pm ET

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aclaris investors under the federal securities laws.

Jul 31, 2019 12:11 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Jul 30, 2019 08:20 pm ET

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (NASDAQ: ACRS)...

Jul 30, 2019 04:41 pm ET

Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Rosi v. Aclaris Therapeutics, Inc. et al., (Case No. 1:19-cv-07118), on behalf of persons and entities that purchased or otherwise acquired Aclaris Therapeutics, Inc.

Jul 30, 2019 04:01 pm ET

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced results from its Phase 2 clinical trial of ATI-501 (AUAT-201 Oral), an investigational...

Jul 30, 2019 11:16 am ET

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of...

Jul 26, 2019 05:08 pm ET

Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell,

NEW YORK, July 26, 2019 /PRNewswire/ --

Jul 24, 2019 08:00 pm ET

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Glancy Prongay & Murray LLP (“GPM”) announces the continuation of its investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of...

Jul 24, 2019 04:29 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Law Offices of Howard G. Smith announces the continuation of its investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of federal...

Jul 23, 2019 11:51 am ET

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi

Jul 22, 2019 05:22 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Jul 16, 2019 01:25 pm ET

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jul 09, 2019 12:15 pm ET

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jul 09, 2019 07:00 am ET

Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No....

Jul 07, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Pintec, Sealed Air, and Aclaris Therapeutics on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Pintec Technology Holdings, Ltd., Sealed Air Corporation, and Aclaris Therapeutics, Inc. on behalf of Investors. Our investigation concerns whether these companies have violated...

Jul 03, 2019 04:01 pm ET

Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of directors, effective July 2, 2019....

Jul 02, 2019 11:38 am ET

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi

Jun 28, 2019 03:40 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Jun 26, 2019 09:30 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Aclaris Therapeutics, electroCore, Pintec, and Sealed Air on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Aclaris Therapeutics, Inc., electroCore, Inc., Pintec Technology Holdings, Ltd., and Sealed Air Corporation on behalf of Investors. Our investigation concerns whether these...

Jun 26, 2019 08:30 pm ET

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Jun 26, 2019 05:54 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Jun 26, 2019 04:01 pm ET

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced results from a Phase 2 clinical trial of ATI-502 (AA-201 Topical), an investigational topical Janus Kinase...

Jun 25, 2019 01:11 pm ET

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jun 24, 2019 05:40 pm ET

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of federal securities laws.

Jun 24, 2019 02:53 pm ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jun 24, 2019 12:02 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Law Offices of Howard G. Smith announces an investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of federal securities laws.

Jun 21, 2019 08:59 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jun 21, 2019 05:40 pm ET

ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Aclaris Therapeutics, Inc. - ACRS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) resulting from allegations that Aclaris may have issued materially misleading business information to the investing public.

Jun 21, 2019 04:29 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Jun 17, 2019 06:00 am ET

Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an...

Jun 14, 2019 04:01 pm ET

Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that management will present a company overview at the 2019 JMP Securities Life...

May 24, 2019 07:00 am ET

Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference

May 08, 2019 04:01 pm ET

Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced its financial results for the first quarter of 2019, and provided an update on its...

Error message

Ad blocking detected

Aclaris Therapeutics Inc (OQ:ACRS)

Business Focus: Biotechnology & Medical Research